BTG plc (BCG) 2016年年度报告「LSE」.pdf

1、BTG plc Annual Report and Accounts 2016Unlocking Value in Interventional MedicineBTG is a growing international healthcare business.We provide innovative products that enable specialist physicians to serve their patients better.We focus on Interventional Medicine therapies for cancer,emphysema and v

2、ascular disorders,and Specialty Pharmaceuticals for acute care uses.Key achievements in 2015/16April 2015Commenced direct sales of DC Bead in EuropeMay 2015REVOLENS study in France of PneumRx Endobronchial Coils meets primary endpointJune 2015First patients in Singapore treated with TheraSphere Augu

3、st 2015Health Canada approves VarithenaDecember 2015RENEW pivotal Phase III study in the US of PneumRx Coils meets all endpoints January 2016First patients in South Korea treated with TheraSphere February 2016First patients in the US treated with LC Bead LUMI March 2016First patients treated with Vi

4、stogardSuccessful study using CroFab for the treatment of copperhead snake envenomation Governance Board of Directors34Corporate Governance report36Audit Committee report48Nomination Committee report 52Directors remuneration report54Directors report 76Statement of directors responsibilities 78Strate

5、gic Report Market overview02Business model04Chairmans statement06Chief Executive Officers review07Business review09Our objectives:progress and priorities10Oncology12Vascular14Pulmonology16Specialty Pharmaceuticals18People and practices19Group financial review22Risk management and principal risks27Vi

6、ability statement29Financials Independent auditors report80Consolidated income statement83Consolidated statement of comprehensive income84Consolidated statement of financial position85Consolidated statement of cash flows86Consolidated statement of changes in equity87Notes to the consolidated financi